Pluristem's PLX Cells Show Efficacy In Treating Lung Disease
06 Aug 2012
Statistically significant animal model results indicate PLX cells could improve the lives of people worldwide with interstitial lung disease in a four billion dollar market
Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR), a leading developer of placenta-based cell therapies, today announced the results of new preclinical tests that show its PLacental eXpanded (PLX) cells may be effective in reducing pulmonary fibrosis and improving lung function in a group of diseases collectively called interstitial lung disease (ILD). ILD includes the pulmonary insults occurring in the lung following its exposure to drugs, radiation or toxic chemicals and the pulmonary complications of systemic autoimmune diseases. More than 200,000 people have been diagnosed with ILD in the United States, and nearly five million people have been diagnosed worldwide. It is estimated that more than 40,000 patients die each year from ILD.
Read more here:
http://www.medicalne...ases/248620.php
0
Improving Life for ILD Patients
Started by Dee, Aug 13 2012 02:43 PM
2 replies to this topic
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
